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I. INTRODUCTION
This study proposes a placebo-controlled pharmacological augmentation of prolonged exposure (PE) therapy provided to OIF/OEF for the treatment of PTSD. The strategy involves the oral administration of the synthetic glucocorticoid, hydrocortisone (Cortef) or placebo prior to the last 8 of 10 treatment sessions. The rationale for this is based on animal studies demonstrating beneficial effects of glucocorticoids (GCs) on aspects of learning relevant to hypothesized mechanisms involved in PE, and on recent clinical findings demonstrating positive effects of GCs on learning, and in reducing traumatic memories in trauma-exposed persons. That PE does not appear to be as effective in the treatment of combat-associated PTSD as in civilian samples further underscores the importance of developing strategies to improve outcome of this treatment among veterans with PTSD. Further, combat veterans demonstrate substantial cognitive alterations, which may or may not be associated with PTSD that may contribute to functional disability, and may affect treatment response. This adds to the relevance of testing the effects of GC administration on PTSD treatment, as evidence suggests that exogenous GCs may improve working memory among veterans.
The primary aim is to determine the effectiveness of Hcort as an augmentation for PE on PTSD symptoms throughout the course of treatment and at follow-up. If pre-session hydrocortisone enhances the effects of treatment, this will identify an important therapeutic strategy for combat veterans. We aim to assess the effects of PE on related clinical and functional measures and on cognitive performance. We aim to correlate the effect of each treatment on PTSD symptoms and cognition to determine whether their alterations are linked. We aim to determine whether biological measures change over treatment, and whether these changes are associated with outcome in the absence or presence of GC augmentation.
Supplemental funding for additional biomarkers
In the last year the aims of the original DOD Hcort/placebo treatment study were enlarged in association with the receipt of plus-up funds to expand the neuroendocrine markers of the initial proposal to include a panel of biomarkers chosen to be identical to several of those obtained n a collaborative cross-sectional study of OIF/OEF returnees entitled 'Biomarkers in PTSD' (PI: Charles Marmar MD; Co-PI: Rachel Yehuda, PhD, and others). Evaluation of biomarkers in the context of a treatment study permits an assessment of the extent to which each (or a subset) may predict or be associated with treatment response. Evaluation of biomarkers in relation to the current treatment study additionally permits assessment of whether any of the chosen biomarkers are differentially affected by the intermittent administration of hydrocortisone prior to treatment sessions in which imaginal exposure takes place. As it was important that the additional biological assessments be incorporated into the current treatment protocol as early as possible, initial funding for this work was provided as a 'plus-up' supplement to the treatment study. For the next two years, however, supplemental funds will be provided as a separate grant with a distinct project number. The novel measures explore molecular, cellular, immune, and neurochemical indices. Specific measures include genotyping and gene expression studies of the glucocorticoid receptor (by Yehuda/Buxbaum at MSSM); evaluation of cellular metabolic indices in collaboration with Owen Wolkowitz, MD and colleagues at UCSF; telomere length and lymphocyte telomerase activity in collaboration with Elizabeth H. Blackburn, PhD; metabolomics and proteomics with Marti Jett and Lee hood (no funding was requested for the latter studies) 1 ; cytokines, and additional neurochemical (BDNF and endocannabinoids) and steroid indices (urinary glucocorticoid metabolites assessed by CGMS, and enzyme indices). An inclusive list of specific supplemental biological measures is provided in Table 1 (Appendix) and described in Task 4 of the Statement of Work (below). (accomplished)  Create regulatory binders, case report forms and database template; establish data input procedures.
(accomplished)  Mobilize existing resources within the JJP VAMC so as to identify potentially eligible OIF/OEF veterans, and within the PTSD clinic to identify potential subjects at intake and at later phases of treatment. Background with respect to the basic competence in PE of the providers in this study: Three of the therapists who perform PE as part of this research study have been certified by the VA to perform prolonged exposure. This 'certification' was instituted in association with the nation-wide 'roll-out' of PE as a mandated treatment offering for PTSD in the VA. Two therapists were asked (but declined) to serve as PE supervisors on a national level. Further, within our research team, a rigorous process of training and review is required before a therapist is permitted to provide research-associated prolonged exposure. For this internal 'certification,' the complete audiotapes of the entire treatment of two recipients of non-research-related PE are reviewed by a VA certified, and research qualified psychologist. The patients whose treatment is thus reviewed for training purposes would otherwise have been appropriate for the current protocol (or for the treatment studies described above) -but perhaps would not have been included for medical reasons, etc. In addition to audiotape review, the training psychologist provides weekly supervision to the PE provider. Only after completion of this review and supervision, and a determination that the psychologist in training/under review is capable of providing PE in a strictly adherent manner, is a therapist permitted to provide PE within a treatment study. Thus, the level of competence among our PE providers is considerable, and it is relatively `unlikely that audiotape review will uncover clinically impactful deviations from the manualized optimal technique.
We have adopted the following procedure for assessing treatment fidelity. As each of the providers participating in this study is qualified to perform fidelity monitoring, we will ask each PE 'certified' provider to rate two of his/her colleagues. Two audiotapes from sessions 3-6 and two from sessions 7-10 will be rated per therapist; the sessions need not be from the same participant(s). A PE session rating form will be used. Melissa D. Altman, PhD will ensure that the ratings are accomplished in a reasonable time frame, and make the results available to the PI and co-Investigators on the project. This procedure is in keeping with the recommendations and procedures used by Paula P. Schnurr, PhD, an expert in the provision and assessment of manualized therapies. 1,2 Details of a plan to accomplish the fidelity ratings were not articulated in the original protocol. We believe the above procedures, with the DOD's approval, will serve to ensure that the treatments provided in this study are faithful to the intent and practice of manualized PE. (accomplished)  Create regulatory binders, case report forms and database template; establish data input procedures.
(accomplished)  Mobilize existing resources within the JJP VAMC so as to identify potentially eligible OIF/OEF veterans, and within the PTSD clinic to identify potential subjects at intake and at later phases of treatment. Total projected number of subject enrollment
To accomplish the objectives 80 OIF/OEF must be randomized (with 40 in each of the two groups).
Of the 80 randomized, we anticipate 60 will complete all study procedures. This necessitates evaluating 100 study participants and screening 125 subjects. b. Number of subjects enrolled to date Table 3 (Appendix) provides a schematic of subject flow, which is described in greater detail below.
Consent and pre-treatment diagnostic evaluation for eligibility: To date, 20 veterans have been consented for the study, 18 of whom were consented since the last annual report was submitted. Of the 20 consenters, 3 discontinued their participation in the study prior to completing any study procedures and 3 currently await initiation of the medical and psychological pre-treatment evaluation. 14 have completed the medical and psychological evaluation for the study. Of these 14, 12 participants were deemed eligible for the study and 2 were determined to be ineligible. Specifically, 1 participant was considered medically ineligible due to laboratory indications of new onset diabetes -and was instead referred to a similar treatment study for which he would be eligible. The other 1 participant was deemed ineligible following the psychological evaluation due to an insufficient CAPS score of 51 -and was also referred to another similar treatment study with a lower pre-treatment CAPS threshold, which he completed.
Pre-treatment research evaluation and treatment participation: Of the 12 participants deemed eligible for the study to date, 11 have completed all pre-treatment evaluation study procedures, which include the completion of self reports, cognitive testing, 24-hour urine, a diurnal saliva collection, and two blood draws (DST day 1 and DST day 2). 1 of the 12 participants is waiting to complete the pretreatment evaluation as he expressed a desire to be treated by the psychologist assigned to his case who will be on maternity leave until early September, 2012. In total, 11 participants have been randomized. Of these 11, 5 have completed treatment4 are currently in treatment, and 2 dropped out after treatment initiation (1 after PE session #1, and 1 after PE session #5). The first participant suffered a leg injury and was distracted by physical therapy appointments, while the second in the midst of divorce proceedings, and found concurrent PE therapy too stressful.
Post-treatment and follow-up evaluations: Of the 5 participants who completed treatment, all 5 have additionally completed their post-treatment evaluation, which includes a clinician rated psychological evaluation for post-treatment diagnosis (using the MINI), a PTSD assessment (CAPS), self reports, cognitive testing, 24-hour urine, diurnal saliva collection, and two blood draws (DST day 1 and DST day 2). The 3-month follow-up evaluation is identical to that performed at pre-and post-treatment. At this time, all 5 participants who completed their post-treatment evaluation have also completed all follow-up evaluation procedures.
Summary: In total, 20 participants have been consented, 11 have completed pre-treatment evaluations and been randomized, 5 have finished post-treatment and follow-up evaluations.
c.
A description of barriers that are hindering subject enrollment efforts HRPO approval to begin this study was provided on March 28, 2010. The first subject signed consent on 4.28.11. It took until 11/09 for the first set of procedural amendments to be approved at the JJP VAMC and at the MSSM. In addition, there was competition for recruitment into this treatment protocol during the first year or more of funding. Our first effort to test the idea of hydrocortisone (Hcort) augmentation of PE therapy took the form of a small protocol, supported by the MIRECC. A case report of two treatment completers from this initial study was published in Yehuda et al.2010 . 1 Following our experience with this small pilot, and using the MIRECC supported protocol as preliminary data for a subsequent grant, we rewrote the study as a somewhat larger but still preliminary treatment protocol, which was funded by the Lightfighter Trust. This preliminary protocol proposed to study 30 veterans with PTSD (completers), and was originally designed to recruit only OIF/OEF subjects. After receiving funding for the current protocol, however, it became apparent that we had two very similar studies which purported to recruit the identical sample. Our IRB requested that we address this overlap. We submitted and were approved for several amendments aimed to differentiate the two studies. The most significant of these was a change in the Lightfighter Trust protocol which opened the study to veterans of any military conflict. Several procedural amendments, enumerated above (in the annotations to the original Statement of Work), to the DOD Hcort study (our moniker for the current protocol) served to further distinguish the studies as well. The Lightfighter Trust protocol is still ongoing, but in the last weeks of funding. 
d. Solutions to overcome difficulties with subject enrollment
In the last few months, our original DOD funded PE study comparing PE treatment to an inactive 'Minimal Attention' condition --has terminated recruitment. This further reduces competition for enrollment into research related PE treatment protocols in the PTSD Clinic. At the present time, our strategy is to enroll into the Lightfighter Trust study only OIF/OEF veterans who would not meet criteria for the current DOD funded Hcort/placebo treatment study.
An important research development serves to enhance recruitment into the DOD funded Hcort/placebo treatment study. The DOD 'Biomarkers in PTSD' study (PI: C. Marmar, MD; Co-PI R. Yehuda, PhD, among others) actively recruits through advertisements OIF/OEF veterans with and without PTSD. This is a cross-sectional study which includes a diagnostic assessment, administration of the CAPS, completion of several self-reports, and cognitive assessment. An MRI performed at NYU is an additional procedure. Veterans, often new to the JJP VAMC, who are evaluated as part of the Biomarkers in PTSD study, and who express a desire for treatment, are introduced to the possibility of participation in the DOD Hcort study.
It is a consequence of the interest developed in biomarkers as a result of the latter multi-center protocol that we have received additional funding to augment the original neuroendocrine battery for the DOD Hcort study with additional biomarkers. By collecting the expanded biomarker panel in association with the current treatment study (see Table 1 ), we will be able to explore which, if any, of the PTSD associated molecular, cellular, inflammatory and neurochemical markers might predict or be associated with positive treatment response to PE. This will as well provide an invaluable additional dimension to the data derived from the DOD funded 'Biomarkers in PTSD' study. Table 4 (Appendix) summarizes the research procedures accomplished to date. As stated above, three subjects discontinued participation prior to completing any research procedures, so no data is available for them. Of the 14 participants who completed a pre-treatment psychological evaluation, only 12 met inclusion criteria. Consequently descriptive data is presented for these 12 only.
III. KEY RESEARCH ACCOMPLISHMENTS
Table 5 (Appendix) presents the descriptive results of psychological assessments, self-reports, and neuroendocrine data that is currently available for all subjects (i.e., whether they received Hcort or placebo during treatment). Thus, complete psychological and biological data is shown for 12 included subjects at pre-treatment and either 4 or 5 subjects at post-treatment and follow-up evaluations, depending on the number of neuroendocrine assay results available to date. Review of the CAPS data presented in Table 5 suggests that avoidance continues to improve between post-treatment and follow-up evaluations, without consideration of the treatment arm of study (i.e., without consideration of the Hcort/ placebo conditions). This is also seen in self-ratings of avoidance (PSS-SR avoidance subscale), but the trend is less pronounced. A similar trend is descriptively apparent for decrement in the Post-Trauma Cognitions Inventory ratings for 'Negative -Self.'
For the neuroendocrine assessments, there appear to be increases in DHEA and DHEAS between the posttreatment and follow-up evaluations. A different pattern is suggested for glucocorticoid indices, where the treatment associated change may appear between the pre-and post-treatment evaluations. Specifically, the latter pattern is apparent for lymphocyte lysozyme IC 50-DEX , percent suppression of cortisol, and the pre-to post-Dex change in plasma cortisol. Clearly with only 5 treatment completers in this sample, even descriptive inferences from these data will likely change as the study progresses. It would be interesting if one of the findings of this investigation was that treatment associated glucocorticoid alterations prefigured consolidation of behavioral gains resulting from treatment, which continued to consolidate over several weeks following treatment termination.
Importantly, the 'data' shown in Table 5 is presented primarily to illustrate that we are performing all steps required to meet the aims of the study, and can manipulate the data to create the outcome variables listed in the protocol. We have not presented the results of the cognitive assessments, but the raw data is available from which specific measures of performance will be derived. Additionally, as we routinely batch assays, glucocorticoid receptor binding has not yet been measured.
IV. REPORTABLE OUTCOMES
There are no reportable outcomes to date.
V. CONCLUSION
Although the current study suffered a substantial delay in its initiation, we are now fully operational. The 'Biomarkers for PTSD' study not only provides a steady stream of newly recruited veterans into research within our Clinic, but is now synergistically positioned scientifically as well. The addition of molecular, cellular, inflammatory, and neurochemical biomarkers --the majority of those assessed in the 'Biomarkers for PTSD' study -will augment the applicability and importance of the current treatment study immeasurably. We are grateful to the DOD for this opportunity. Table 3 . Summary of participant flow to date.
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